Methylazoxymethanol Acetate (MAM) Model Development Service

Are you currently facing complex challenges in modeling psychiatric disorders, such as a lack of translatable preclinical models or difficulties in replicating human-like neurodevelopmental pathology? Our methylazoxymethanol acetate (MAM) model development services help you accelerate drug discovery by providing a highly validated and reproducible preclinical model. We achieve this through our precise and well-established gestational dosing protocols and comprehensive phenotyping platforms, ensuring your research is built on a solid foundation.

Workflow Advantages Available Models Offerings Related Services FAQs

How Our MAM Model Can Assist Your Project

Our MAM model development services provide a clear path to understanding the neurobiology of schizophrenia and related disorders. We deliver a meticulously generated and thoroughly characterized animal model that exhibits the key neuropathological and behavioral endophenotypes required for robust preclinical studies. Our solutions enable you to screen drug candidates, investigate disease mechanisms, and validate therapeutic targets with high confidence.

Discover How We Can Help - Request a Consultation

Fig.1 Workflow of our Maternal Immune Activation (MIA) Model Development Services. (Creative Biolabs Original)

Workflow

Required Starting Materials	To initiate a project, clients typically provide a detailed research plan, including specific study objectives and a timeline. We also need any relevant preliminary data and, most importantly, the exact strain and sex of the rodents to be used in the study to ensure consistency and reproducibility.
Final Deliverables	Upon completion, you will receive a detailed Study Report with all methods and findings, a Raw Data File containing all numerical data from behavioral and molecular analyses, and a Summary Presentation highlighting key results and conclusions.
Estimated Timeframe	The typical timeframe for a full-service MAM model project ranges from 12 to 16 weeks, depending on the number of groups, the complexity of the phenotyping battery, and the specific research goals.

Why Choose Us?

At Creative Biolabs, our two decades of experience in preclinical neurobiology set us apart. We have a deep understanding of the intricacies of the MAM model, ensuring a higher success rate and more reliable data than can be achieved through internal or less-experienced external labs. Our services are built on a foundation of scientific rigor, a commitment to quality, and a collaborative partnership approach.

Experience the Advantage - Get a Quote Today

Customer Reviews

"Using CBL's MAM model services in our research has significantly improved our ability to study the social and behavioral deficits associated with schizophrenia. The reproducibility and consistency of their models are unmatched." - A. a be, Lead Scientist

"The detailed histological analysis provided by CBL was a game-changer for our project. It allowed us to confirm the targeted neuropathology and provided key evidence for our grant application." - B. o ye, Principal Investigator

"The team at CBL guided us through the entire process, from design to data delivery. Their expertise helped us streamline our project and focus on our core research questions. The PPI data was particularly clean and reliable." - J. a me, Senior Research Fellow

Methylazoxymethanol Acetate (MAM) Model

The MAM model is based on the neurotoxic effects of methylazoxymethanol acetate, a compound that selectively targets dividing cells. When administered during a specific gestational window (e.g., embryonic day 17 in rodents), MAM disrupts the normal migration and proliferation of neural precursor cells. This interference leads to a characteristic set of brain abnormalities, including hippocampal disorganization, cortical hypoplasia, and ventricular enlargement. Beyond these structural changes, MAM models exhibit a broad spectrum of behavioral deficits that are highly relevant to human conditions, such as cognitive dysfunction, social deficits, and sensorimotor gating deficits. These features make the MAM model an invaluable tool for studying the neurobiology of schizophrenia and other developmental neuropsychiatric conditions.

Fig.2 Young rats that were exposed to methylazoxymethanol acetate (MAM) before birth exhibit behavioral abnormalities. (OA Literature) Fig.1 Behavioral abnormalities in prenatally methylazoxymethanol acetate (MAM)-exposed young rats.¹

What We Can Offer

At CBL, our MAM model development services are designed to provide a comprehensive, end-to-end solution for your neurodevelopmental research needs. We understand that every project is unique, which is why we specialize in creating highly customized services that align with your specific scientific goals.

Customized Service: We provide a tailored approach to MAM model development, optimizing the gestational timing, dose, and phenotyping battery to suit your unique project requirements.
Reproducible Models: Our well-established protocols and strict quality control ensure the high reproducibility and consistency of our models, which is critical for obtaining reliable and translatable data.
Comprehensive Phenotyping: We offer a full suite of behavioral, histological, and molecular assays to provide a complete picture of the model's neuroanatomical and behavioral phenotype.
Quality Assurance: Our services are backed by a robust quality system and rigorous process analytical techniques (PAT), ensuring the integrity and reliability of all data.
Dedicated Expertise: With over 20 years of experience in preclinical neurobiology, our team provides unparalleled scientific and technical support to guide your project from concept to completion.
Support for Downstream Applications: We ensure our models are suitable for a range of applications, including drug screening, target validation, and investigation of underlying disease mechanisms.

Related Services

To support your comprehensive research needs, CBL offers a suite of complementary services that can be integrated with our MAM model development services.

Target Identification & Validation
Compound Screening & Profiling
Pharmacokinetic/Pharmacodynamic (PK/PD) Studies
Neuroinflammation Research Models

FAQs

Q Can your services be tailored to a specific research focus, such as a particular gene or signaling pathway?

A Yes, our services are highly customizable. We can modify the study design to include specific behavioral assays or molecular analyses that are relevant to your research focus. Our team works closely with you to ensure the model and phenotyping battery are perfectly aligned with your project goals, providing you with the most relevant and actionable data.

Q How does the MAM model compare to genetic models of schizophrenia?

A The MAM model is a powerful complement to genetic models. While genetic models can explore a specific gene's role, the MAM model captures the polygenic and environmental components of the disease, providing a more holistic view of the disorder. Combining these two approaches can provide a more comprehensive understanding of complex gene-environment interactions.

To learn more about our services and discuss how we can support your project, please reach out to our team of specialists.

Contact Our Team for More Information and to Discuss Your Project.

Reference

Kim, Eun-Hee, et al. "A new rat model of epileptic spasms based on methylazoxymethanol-induced malformations of cortical development." Frontiers in Neurology 8 (2017): 271. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fneur.2017.00271

For Research Use Only. Not For Clinical Use.

In Vivo Services

Hot Products

Antibodies

Cells

Kits

Tracers

Gene Therapy Tools

Biospecimens

Cell Assay Reagents